Overview Dividends

(MD) Mednax - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US58502B1061

Neonatology, Anesthesia, Maternal-Fetal, Teleradiology, Pediatric

MD EPS (Earnings per Share)

EPS Growth (3Y CAGR): 10.78%
EPS Trend (3Y Correlation): 12.0%

MD Revenue

Revenue Growth (3Y CAGR): -1.59%
Revenue Trend (3Y Correlation): -46.9%

Description: MD Mednax

Mednax Inc (NYSE:MD) is a healthcare services company listed on the New York Stock Exchange. As a provider of healthcare services, the companys performance is influenced by factors such as healthcare spending, government regulations, and demographic trends.

The stocks recent price movement indicates a potential uptrend, with the short-term and long-term moving averages suggesting a bullish sentiment. The stocks beta of 1.209 implies a moderate level of volatility relative to the overall market.

From a fundamental perspective, Mednaxs market capitalization stands at approximately $1.4 billion, with a price-to-earnings ratio of 12.34 and a forward P/E of 9.96. The companys return on equity is 14.09%, indicating a relatively strong ability to generate profits from shareholder equity.

Key performance indicators (KPIs) to monitor for Mednax include revenue growth, earnings per share (EPS), and operating margins. The companys financial health is also influenced by factors such as accounts receivable, days sales outstanding (DSO), and cash flow generation. Economic drivers that impact the healthcare services industry include government reimbursement rates, demographic trends, and technological advancements.

To evaluate Mednaxs future prospects, its essential to analyze the companys competitive positioning, growth strategies, and ability to adapt to changing regulatory environments. Key metrics to watch include same-store sales growth, patient volume, and revenue diversification. Additionally, the companys ability to manage costs, invest in technology, and expand its service offerings will be crucial in driving long-term success.

MD Stock Overview

Market Cap in USD	1,499m
Sub-Industry	Health Care Services
IPO / Inception	1995-09-19

MD Stock Ratings

Growth Rating	-0.52%
Fundamental	60.5%
Dividend Rating	-
Return 12m vs S&P 500	29.7%
Analyst Rating	3.75 of 5

MD Dividends

Currently no dividends paid

MD Growth Ratios

Growth Correlation 3m	65.9%
Growth Correlation 12m	30.8%
Growth Correlation 5y	-75.3%
CAGR 5y	-2.73%
CAGR/Max DD 3y	-0.04
CAGR/Mean DD 3y	-0.09
Sharpe Ratio 12m	0.31
Alpha	39.44
Beta	0.760
Volatility	44.38%
Current Volume	573.3k
Average Volume 20d	753k
Stop Loss	16 (-3.4%)
Signal	-0.69

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income (109.9m TTM) > 0 and > 6% of Revenue (6% = 116.4m TTM)

FCFTA 0.11 (>2.0%) and ΔFCFTA 6.19pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 14.02% (prev 5.95%; Δ 8.07pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.12 (>3.0%) and CFO 244.6m > Net Income 109.9m (YES >=105%, WARN >=100%)

Net Debt (424.8m) to EBITDA (203.5m) ratio: 2.09 <= 3.0 (WARN <= 3.5)

Current Ratio 1.80 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (86.9m) change vs 12m ago 4.23% (target <= -2.0% for YES)

Gross Margin 24.36% (prev 19.87%; Δ 4.48pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 94.73% (prev 100.4%; Δ -5.63pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 4.72 (EBITDA TTM 203.5m / Interest Expense TTM 38.1m) >= 6 (WARN >= 3)

Altman Z'' 0.99

(A) 0.13 = (Total Current Assets 613.0m - Total Current Liabilities 341.0m) / Total Assets 2.10b

(B) -0.09 = Retained Earnings (Balance) -188.5m / Total Assets 2.10b

(D) -0.15 = Book Value of Equity -187.5m / Total Liabilities 1.27b

Total Rating: 0.99 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 60.52

1. Piotroski 5.50pt = 0.50

2. FCF Yield 13.33% = 5.0

3. FCF Margin 12.15% = 3.04

4. Debt/Equity 0.74 = 2.23

5. Debt/Ebitda 3.04 = -1.83

6. ROIC - WACC 2.66% = 3.32

7. RoE 14.09% = 1.17

8. Rev. Trend -46.91% = -3.52

9. EPS Trend 11.98% = 0.60

What is the price of MD shares?

As of September 17, 2025, the stock is trading at USD 16.57 with a total of 573,332 shares traded.
Over the past week, the price has changed by -2.24%, over one month by +3.30%, over three months by +19.90% and over the past year by +54.14%.

Is Mednax a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, Mednax is currently (September 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 60.52 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MD is around 16.69 USD . This means that MD is currently overvalued and has a potential downside of 0.72%.

Is MD a buy, sell or hold?

Mednax has received a consensus analysts rating of 3.75. Therefor, it is recommend to hold MD.

Strong Buy: 3
Buy: 0
Hold: 5
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the MD price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	16.7	0.8%
Analysts Target Price	16.7	0.8%
ValueRay Target Price	18.3	10.3%

Last update: 2025-09-03 04:42

MD Fundamental Data Overview

Market Cap USD = 1.50b (1.50b USD * 1.0 USD.USD)
CCE Cash And Equivalents = 348.3m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 13.2385
P/E Forward = 10.6838
P/S = 0.7722
P/B = 1.7976
P/EG = 0.88
Beta = 1.209
Revenue TTM = 1.94b USD
EBIT TTM = 179.7m USD
EBITDA TTM = 203.5m USD
Long Term Debt = 583.9m USD (from longTermDebt, last quarter)
Short Term Debt = 35.7m USD (from shortTermDebt, last quarter)
Debt = 619.6m USD (Calculated: Short Term 35.7m + Long Term 583.9m)
Net Debt = 424.8m USD (from netDebt column, last quarter)
Enterprise Value = 1.77b USD (1.50b + Debt 619.6m - CCE 348.3m)
Interest Coverage Ratio = 4.72 (Ebit TTM 179.7m / Interest Expense TTM 38.1m)
FCF Yield = 13.33% (FCF TTM 235.9m / Enterprise Value 1.77b)
FCF Margin = 12.15% (FCF TTM 235.9m / Revenue TTM 1.94b)
Net Margin = 5.66% (Net Income TTM 109.9m / Revenue TTM 1.94b)
Gross Margin = 24.36% ((Revenue TTM 1.94b - Cost of Revenue TTM 1.47b) / Revenue TTM)
Tobins Q-Ratio = -9.44 (set to none) (Enterprise Value 1.77b / Book Value Of Equity -187.5m)
Interest Expense / Debt = 1.47% (Interest Expense 9.13m / Debt 619.6m)
Taxrate = 28.58% (15.7m / 55.0m)
NOPAT = 128.4m (EBIT 179.7m * (1 - 28.58%))
Current Ratio = 1.80 (Total Current Assets 613.0m / Total Current Liabilities 341.0m)
Debt / Equity = 0.74 (Debt 619.6m / last Quarter total Stockholder Equity 833.8m)
Debt / EBITDA = 3.04 (Net Debt 424.8m / EBITDA 203.5m)
Debt / FCF = 2.63 (Debt 619.6m / FCF TTM 235.9m)
Total Stockholder Equity = 780.1m (last 4 quarters mean)
RoA = 5.23% (Net Income 109.9m, Total Assets 2.10b )
RoE = 14.09% (Net Income TTM 109.9m / Total Stockholder Equity 780.1m)
RoCE = 13.18% (Ebit 179.7m / (Equity 780.1m + L.T.Debt 583.9m))
RoIC = 9.20% (NOPAT 128.4m / Invested Capital 1.39b)
WACC = 6.55% (E(1.50b)/V(2.12b) * Re(8.82%)) + (D(619.6m)/V(2.12b) * Rd(1.47%) * (1-Tc(0.29)))
Shares Correlation 3-Years: 72.73 | Cagr: 0.44%
Discount Rate = 8.82% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 78.96% ; FCFE base≈181.7m ; Y1≈224.1m ; Y5≈382.4m
Fair Price DCF = 64.50 (DCF Value 5.62b / Shares Outstanding 87.1m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 11.98 | EPS CAGR: 10.78% | SUE: 1.48 | # QB: True
Revenue Correlation: -46.91 | Revenue CAGR: -1.59%

Additional Sources for MD Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle